Skip to main content
COAG
NASDAQ Life Sciences

Sutacimig Cuts Prothrombin Time Over 50% After Single Dose in Two Patients

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$43.1
Mkt Cap
$2.013B
52W Low
$23
52W High
$55.42
52W Position info
87% above low
Off High info
22% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

COAG sits 87% above its 52-week low of $23.

Summary

Two patients with severe congenital Factor VII deficiency received a single sutacimig dose and both saw prothrombin time shorten by more than 50%. One participant with available data showed roughly 5x accumulation of endogenous FVII(a) through Day 22, which points to sustained target engagement. The readout is thin — two patients for the PT effect and exposure data from just one — so it is early proof of mechanism rather than proof of benefit. Separately, HMB-003 cut severe bleeding days in a monkey model, a preclinical result that does not establish human efficacy. This follows the August 10-Q, where the FDA endorsed a Phase 3 trial for sutacimig and $457.5M in cash funds operations into 2029. HMB-003 Phase 1 human data are expected mid-2027 and are the next real test.

At the time of this announcement, COAG was trading at $43.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $23.00 to $55.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

COAG - Latest Insights

COAG
Nov 10, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.81
Real-time Price: $39.86 info
Change: -$2.95 (-7%) info
Market Cap: $1.863B info
COAG
Sep 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $40.97
Real-time Price: $39.86 info
Change: -$1.11 (-3%) info
Market Cap: $1.863B info
COAG
Aug 11, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $51.74
Real-time Price: $39.86 info
Change: -$11.88 (-23%) info
Market Cap: $1.863B info
COAG
Aug 11, 2026, 7:50 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $49.87
Real-time Price: $39.86 info
Change: -$10.01 (-20%) info
Market Cap: $1.863B info
COAG
Aug 11, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.87
Real-time Price: $39.86 info
Change: -$10.01 (-20%) info
Market Cap: $1.863B info